A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Thomas Powles,Matthew James Wheater,Omar S Din,T Geldart,E Boleti,A D Stockdale,Santhanam Sundar,Angus Robinson,Imtiaz Ahmed,Akhila Wimalasingham,Wendy Burke,Shahjalal Sarker,Syed Ather Hussain,Christy Ralph

European Urology（2016）

引用 79|浏览14

暂无评分

摘要

This study is the first randomised trial to show that AZD2014 (a TORC1 and TORC2 inhibitor) was less active than everolimus (TORC1 inhibitor) in metastatic renal cell carcinoma. This study contradicts preclinical data that support the use of broader spectrum mammalian target of rapamycin inhibitors.

查看译文

关键词

Renal cancer,mTOR,TORC2,Survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要